Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Foghorn Therapeutics (FHTX)

April 22, 2026 6:41 AM EDT Send to a Friend
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $13.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login